My ePortfolio Register   

Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed or refractory myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.03.17
Views: 1304

Dr Suzanne Lentzsch - Columbia University, New York, USA

Dr Lentzsch speaks with ecancer at the 16th International Myeloma Workshop about the CASTOR trial.

The CASTOR trial is a phase III randomised controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma.

Dr Lentzsch also spoke with ecancer about the future of precision medicine in treating myeloma.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence